A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis.

Trial Profile

A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Tillotts Pharma
  • Most Recent Events

    • 24 Jan 2012 Actual patient number (281) added as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top